Abdominal obesity with hypertriglyceridaemia, lipoprotein(a) and apolipoprotein A-I determine marked cardiometabolic risk

European Journal of Clinical Investigation

Volumn 43, Issue 11, 2013, Pages 1129-1139

  Onat, Altan ^a,b   Can, Günay ^b   Örnek, Ender ^c   Sansoy, Vedat ^d   Aydin, Mesut ^e   Yüksel, Hüsniye ^b  

^a Turkish Society of Cardiology   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Etlik Ihtisas Education Hospital   (Turkey)

^d ISTANBUL UNIVERSITY   (Turkey)

^e DUZCE UNIVERSITY   (Turkey)

Author keywords

'hypertriglyceridemic waist' phenotype; Abdominal obesity; Coronary heart disease; Gender difference; Lipoprotein(a) apolipoprotein A I

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; ALCOHOL CONSUMPTION; ARTICLE; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; AGE DISTRIBUTION; COMPLICATION; CORONARY DISEASE; EPIDEMIOLOGY; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; OBESITY, ABDOMINAL; RISK FACTOR; SEX RATIO; TURKEY;

AGE DISTRIBUTION; APOLIPOPROTEIN A-I; CORONARY DISEASE; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN(A); MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, ABDOMINAL; PROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; TURKEY;

EID: 84885434046     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12150     Document Type: Article

References (35)

1. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Alméras N et al. Hypertriglyceridemic waist: a marker of atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000;102:179-84.
2. St-Pierre J, Lemieux I, Perron B, Brisson D, Santuré M, Vohl MC et al. Relation of the "hypertriglyceridemic waist" phenotype to earlier manifestations of coronary artery disease in patients with glucose intolerance and type 2 diabetes mellitus. Am J Cardiol 2007;99:369-73.
3. Arsenault BJ, Lemieux I, Després JP, Wareham NJ, Kastelein JJP, Khaw K-T et al. The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk Prospective Population Study. CMAJ 2010;182:1427-32.
4. Gomez-Huelgas R, Bernal-Lopez MR, Villalobos A, Mancero-Romero J, Baca-Osorio AJ, Jansen S et al. Hypertriglyceridemic-waist: an alternative to the metabolic syndrome? Results of the IMAP Study (multidisciplinary intervention in primary care). Int J Obes 2011;35:292-9.
5. Yu D, Huang J, Hu D, Chen J, Cao J, Li J. Is an appropriate cutoff of hypertriglyceridemic waist designated for type 2 diabetes among Chinese adults? Clin Nutr 2010;29:192-8.
6. Sam S, Haffner S, Davidson MH, D'Agostino RB Sr, Feinstein S, Kondos G et al. Hypertriglyceridemic-waist phenotype predicts increased visceral fat in subjects with type 2 diabetes. Diabetes Care 2009;32:1916-20.
7. De Graaf FR, Schuijf JD, Scholte AJ, Djaberi R, Van Velzen JE, Roos CJ et al. Usefulness of hypertriglyceridemic-waist phenotype in type 2 diabetes mellitus to predict the presence of coronary artery disease as assessed by computed tomographic coronary angiography. Am J Cardiol 2010;106:1747-53.
8. Kahn HS, Valdez R. Metabolic risks identified by the combination of enlarged waist and elevated triacylglycerol concentrations. Am J Clin Nutr 2003;78:928-34.
9. Esmailizadeh A, Azadbakht L. Increased levels of inflammation among women with enlarged waist and elevated triglyceride concentrations. Ann Nutr Metab 2010;57:77-84.
10. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS et al. Oxidized phospholipids, lipoprotein(a) lipoprotein, and coronary artery disease. N Engl J Med 2005;353:46-57.
11. Edelstein C, Pfaffinger D, Hinman J, Miller E, Lipkind G, Tsimikas S et al. Lysine-phosphatidylcholine adducts in Kringle V impart unique immunological and pro-inflammatory properties to human apolipoprotein(a). J Biol Chem 2003;278:52841-7.
12. Sharp DS, Burchfiel CM, Rodriguez BL, Sharrett AR, Sorlie PD, Marcovina SM. Apolipoprotein A-1 predicts coronary heart disease only at low concentrations of high-density lipoprotein cholesterol: an epidemiological study of Japanese-Americans. Int J Clin Lab Res 2000;30:39-48.
13. Onat A, Hergenç G, Bulur S, Uǧur M, Küçükdurmaz Z, Can G. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 2010;142:72-9.
14. Onat A, Can G, Ayhan E, Kaya Z, Hergenç G. Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks. Metabolism 2009;58:1393-9.
15. Onat A, Kömürcü-Bayrak E, Can G, Küçükdurmaz Z, Hergenç G, Erginel-Unaltuna N. Apolipoprotein A-I positively associated with diabetes in women independently of apo E genotype and apolipoprotein B levels. Nutrition 2010;26:975-80.
16. Onat A, Can G, Yüksel H. Dysfunction of high-density lipoprotein and its apolipoproteins: new mechanisms underlying cardiometabolic risk in the population at large. Arch Turk Soc Cardiol 2012;40:368-85.
17. Onat A, Ceyhan K, Başar Ö, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels - a prospective and cross-sectional evaluation. Atherosclerosis 2002;165:285-92.
18. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001;156:1-10.
19. Onat A, Uyarel H, Hergenç G, Karabulut A, Albayrak S, Can G. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 2007;191:182-90.
20. National Cholesterol Education Expert Panel. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
21. Rose GA, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular Survey Methods. 2nd ed. Geneva: WHO, 1982: pp 124-7.
22. Guey LT, Pullinger CR, Ishida BY, O'Connor PM, Zellner C, Francone OL et al. Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease. Am J Cardiol 2011;108:360-6.
23. Onat A, Can G, Hergenç G, Yazici M, Karabulut A, Albayrak S. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension, diabetes, independent of markers of central obesity and inflammation. Int J Obes 2007;31:1119-25.
24. Sniderman A, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001;135:447-59.
25. The Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and nonvascular mortality. JAMA 2009;302:412-23.
26. Lopez LR, Bruckner TR, Hurley BL, Kobayashi K, Matsuura E. Determination of oxidized low-density lipoprotein (ox-LDL) versus oxLDL/beta2-GPI complexes for the assessment of autoimmune-mediated atherosclerosis. Ann N Y Acad Sci 2007;1109:303-10.
27. Wang J, Gong J, Li H, Niu DM, Han AZ, Wu J. Lipoprotein(a) complexes with beta2-glycoprotein I in patients with coronary artery disease. J Atheroscler Thromb 2012;19:81-9.
28. Onat A, Hergenç G. Low-grade inflammation and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 2011;60:499-512.
29. Ogasawara K, Mashiba S, Hashimoto H, Kojima S, Matsuno S, Takeya M et al. Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease. Clin Chim Acta 2008;397:42-7.
30. Pankhurst G, Wang XL, Wilcken DE, Baernthaler G, Panzenböck U, Raftery M et al. Characterization of specifically oxidized apolipoproteins in mildly oxidized high density lipoprotein. J Lipid Res 2003;44:349-55.
31. Albahrani AI, Usher JJ, Alkindi M, Marks E, Ranganath L, Al-yahyaee S. ApolipoproteinA-I-75 G/A (MI-) polymorphism and lipoprotein(a): anti- vs. pro-atherogenic properties. Lipids Health Dis 2007;6:19.
32. Blackburn P, Lemieux I, Lamarche B, Bergeron J, Perron P, Tremblay G et al. Type 2 diabetes without the atherogenic metabolic triad does not predict angiographically assessed coronary artery disease in women. Diabetes Care 2008;31:170-2.
33. Sam S, Haffner S, Davidson MH, D'Agostino RB Sr, Feinstein S, Kondos G et al. Relationship of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care 2009;32:932-7.
34. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM. Mechanisms of disease: proatherogenic HDL -an evolving field. Nature Clin Pract EndMet 2006;2:504-11.
35. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011;4:337-45.